
Tarsus Pharmaceuticals gains analyst boost after acquiring Alkeus and expanding Stargardt's disease drug pipeline.
Tarsus Pharmaceuticals recently acquired Alkeus Pharmaceuticals, gaining worldwide rights to gildeuretinol, a promising Phase 3 drug for Stargardt's disease, which currently lacks FDA-approved treatments. Analyst Jefferies raised Tarsus' price target...


